Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.

被引：7
|
作者：
Kelly, Ronan Joseph
Lee, Jeeyun
Bang, Yung-Jue
Almhanna, Khaldoun
Murphy, Mariela A. Blum
Catenacci, Daniel V. T.
Chung, Hyun Cheol
Wainberg, Zev A.
Gibson, Michael
Lee, Keun Wook
Bendell, Johanna C.
Denlinger, Crystal S.
Brohawn, Philip Z.
He, Peng
McDevitt, Jennifer
Englert, Judson
Ku, Geoffrey Yuyat
机构：
[1] Johns Hopkins Med, Baltimore, MD USA
[2] Samsung Med Ctr, Seoul, South Korea
[3] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Seoul, South Korea
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Univ Chicago, Med Comprehens Canc Ctr, Chicago, IL 60637 USA
[7] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[8] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
[9] Univ Hosp Case, Med Ctr, Cleveland, OH USA
[10] Seoul Natl Univ, Bundang Hosp, Seoul Natl Univ Coll Med, Seoul, South Korea
[11] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[12] Fox Chase Canc Ctr, Philadelphia, PA USA
[13] MedImmune, Gaithersburg, MD USA
[14] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4031
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors A systematic review and meta-analysis
    Wang, Bi-Cheng
    Li, Peng-Cheng
    Fan, Ji-Quan
    Lin, Guo-He
    Liu, Quentin
    MEDICINE, 2020, 99 (28) : E21273
  • [2] Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
    Kelly, Ronan J.
    Lee, Jeeyun
    Bang, Yung-Jue
    Almhanna, Khaldoun
    Blum-Murphy, Mariela
    Catenacci, Daniel V. T.
    Hyun Cheol Chung
    Wainberg, Zev A.
    Gibson, Michael K.
    Lee, Keun-Wook
    Bendell, Johanna C.
    Denlinger, Crystal S.
    Chee, Cheng Ean
    Omori, Takeshi
    Leidner, Rom
    Lenz, Heinz-Josef
    Chao, Yee
    Rebelatto, Marlon C.
    Brohawn, Philip Z.
    He, Peng
    McDevitt, Jennifer
    Sheth, Siddharth
    Englert, Judson M.
    Ku, Geoffrey Y.
    CLINICAL CANCER RESEARCH, 2020, 26 (04) : 846 - 854
  • [3] Safety and efficacy of durvalumab in combination with tremelimumab in patients with advanced gastric cancer with elevated tumor interferon-γ gene signature
    Ku, Geoffrey
    Lee, Jeeyun
    Lenz, Heinz-Josef
    Chee, Cheng Ean
    Omori, Takeshi
    Lee, Keun-Wook
    Chao, Yee
    Catenacci, Daniel
    Gibson, Michael
    Cohen, Deirdre
    Wainberg, Zev
    Brohawn, Philip Z.
    He, Peng
    Sheth, Siddharth
    Englert, Judson
    Kelly, Ronan
    Bang, Yung-Jue
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma
    Fujiwara, Yutaka
    Takahashi, Yasuo
    Okada, Morihito
    Kishimoto, Takumi
    Kondo, Shunsuke
    Fujikawa, Koshi
    Hayama, Manabu
    Sugeno, Masatoshi
    Ueda, Shinya
    Komuro, Keiko
    Lanasa, Mark
    Nakano, Takashi
    ONCOLOGIST, 2022, 27 (09): : E703 - E722
  • [5] Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer
    Doki, Yuichiro
    Ueno, Makoto
    Hsu, Chih-Hung
    Oh, Do-Youn
    Park, Keunchil
    Yamamoto, Noboru
    Ioka, Tatsuya
    Hara, Hiroki
    Hayama, Manabu
    Nii, Masahiro
    Komuro, Keiko
    Sugimoto, Mariko
    Tahara, Makoto
    CANCER MEDICINE, 2022, 11 (13): : 2550 - 2560
  • [6] COST-EFFECTIVENESS OF TREMELIMUMAB OR TREMELIMUMAB IN COMBINATION WITH DURVALUMAB VS DURVALUMAB AS TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA
    Tang, T.
    Shi, L.
    VALUE IN HEALTH, 2023, 26 (06) : S138 - S138
  • [7] Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
    Song, Xuyang
    Kelley, Robin Kate
    Khan, Anis A.
    Standifer, Nathan
    Zhou, Diansong
    Lim, KyoungSoo
    Krishna, Rajesh
    Liu, Lu
    Wang, Kun
    McCoon, Patricia
    Negro, Alejandra
    He, Philip
    Gibbs, Megan
    Kurland, John F.
    Abou-Alfa, Ghassan K.
    CLINICAL CANCER RESEARCH, 2023, 29 (04) : 754 - 763
  • [8] ARCTIC: Durvalumab plus tremelimumab and durvalumab monotherapy vs SoC in ≥ 3L advanced NSCLC treatment
    Kowalski, D. M.
    Reinmuth, N.
    Orlov, S. V.
    Fischer, J. R.
    Sugawara, S.
    Mandziuk, S.
    Medine, D. M.
    Novello, S.
    Takeda, Y.
    Soo, R. A.
    Park, K.
    McCleod, M.
    Geater, S. L.
    Powell, M.
    May, R.
    Stockman, P.
    Planchard, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Sangro, Bruno
    Morse, Michael
    Zhu, Andrew X.
    Kim, Richard D.
    Cheng, Ann-Lii
    Kudo, Masatoshi
    Kang, Yoon-Koo
    Chan, Stephen L.
    Antal, Joyce
    Boice, Jillian
    Xiao, Feng
    Morris, Shannon R.
    Bendell, Johanna
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Tremelimumab/Durvalumab Demonstrates Safety, Activity in Gastric/GEJ Adenocarcinoma
    Conroy, Russ
    ONCOLOGY-NEW YORK, 2023, 37 (03): : 147 - 148
12345